Compare AbbVie Inc (ABBV) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Yum! Brands, Inc. — how do they compare? AbbVie Inc trades at $254.02 (market cap $449.91B), while Yum! Brands, Inc. trades at $166.96 (market cap $46.16B). The key difference: AbbVie Inc is far larger — about 9.7× Yum! Brands, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | YUM | |
|---|---|---|
Market Cap | $449.91B | $46.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $168.16 |
52-Week Low | $184.85 | $138.21 |
Enterprise Value | $513.38B | $57.43B |
Dividend Yield | 2.72% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.76, down 2.42% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates solid fundamental performance with Q1 2026 earnings beating expectations at $2.65 EPS versus $2.59 expected, continuing a trend of quarterly beats. Revenue growth remains robust at $61.16 billion for 2025, supported by successful portfolio transition beyond Humira patent expiration.
AbbVie presents a compelling investment case with 68% analyst buy ratings and a $266.33 consensus target offering 4.5% upside. Key opportunities include Skyrizi and Rinvoq driving growth, while risks involve patent cliffs in the 2030s and high valuation multiples. The company's dividend aristocrat status and strong cash flow generation support continued shareholder returns.
YUM trades at $167.49, up 1.68% today, near its consensus price target of $174.00. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentals are solid with revenue growth from $7.5B in 2024 to $8.2B in 2025 and a net income margin of 20.48%. Recent news highlights the $2.7 billion sale of Pizza Hut, aimed at streamlining operations and funding a $4 billion share repurchase, signaling strategic focus on KFC and Taco Bell.
The outlook for YUM is cautiously optimistic, supported by earnings beats and strategic divestiture, but high debt levels and competitive pressures pose risks. Analyst consensus leans hold with a 37.25% buy rating, suggesting moderate upside potential. Investors should weigh the benefits of capital returns against execution risks in a challenging consumer discretionary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
